Codon
FEBRUARY 13, 2025
One study from 2008 (also from the Baker lab) reported de novo enzyme catalysts for Kemp elimination — a reaction that opens up a benzisoxazole ring — by running molecular dynamics simulations to sieve through possible designs.
Metabolite Tales Blog
JANUARY 26, 2023
Metabolism of 2022 FDA approved small molecule drugs – Part 1 Does CYP3A4 still rule? By Julia Shanu-Wilson It won’t come as much surprise to learn that of the 17 small molecules* approved by the FDA in 2022, CYP3A4 was the major player in drug metabolism. References Iversen et al., Basic Clin Pharmacol Toxicol.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Metabolite Tales Blog
APRIL 4, 2023
Metabolism of 2022 FDA approved small molecule drugs part 2 Mixing it Up By Julia Shanu-Wilson In Part 1 of this topic we looked at metabolism of the small molecule drugs approved by the FDA in 2022 that were mediated by CYP3A4. 2008 Mar;153 Suppl 1(Suppl 1):S82-9. We hope it was a useful two-parter!
Molecular Design
DECEMBER 31, 2024
My pulse will be quickenin' With each drop of strychnine We feed to a pigeon It just takes a smidgin To poison a pigeon in the park Tom Lehrer, Poisoning Pigeons in the Park | video ** Ill be reviewing the H2024 study (Occurrence of Natural Selection in Successful Small Molecule Drug Discovery) in this post.
New Drug Approvals
DECEMBER 3, 2022
852808-04-9 ABT-737 is a small molecule drug that inhibits Bcl-2 and Bcl-xL , two members of the Bcl-2 family of evolutionarily-conserved proteins that share B cl-2 H omology (BH) domains. “Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.” 2008): 360–367. doi : 10.1038/ncomms11190.
NIH Director's Blog: Drug Development
OCTOBER 11, 2022
For clinical researchers, click chemistry has emerged as a workhorse in drug discovery and the improved targeting of cancer chemotherapies and other small-molecule drugs. Science 2008, 320 (5876), 664–667. [6] 6] Small molecule inhibitors of mucin-type O-glycosylation from a uridine-based library.
New Drug Approvals
SEPTEMBER 29, 2024
link] 01 Aug 2022 Cortexyme is now called Quince Therapeutics You need to be a logged in or subscribed to view this content This small molecule is an orally available protease inhibitor targeting the lysine proteases of the periodontal pathogen Porphyromonas gingivalis. Epub 2008 Dec 29 PubMed. Infect Immun.
Expert insights. Personalized for you.
124 
Let's personalize your content